Kaur N, Gupta I, Singh H et al (2020) Epidemiological and clinical characteristics of 6635 covid-19 patients: a pooled analysis. SN Compr Clin Med 2:1048–1052. https://doi.org/10.1007/s42399-020-00393-y
Article
CAS
PubMed
PubMed Central
Google Scholar
WHO coronavirus disease (COVID-19) dashboard. https://covid19.who.int/table
Li Y-D, Chi W-Y, Su J-H et al (2020) Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 27:104. https://doi.org/10.1186/s12929-020-00695-2
Article
CAS
PubMed
PubMed Central
Google Scholar
Scobie HM, Johnson AG, Suthar AB et al (2021) Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status — 13 U.S. jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 70:1284–1290. https://doi.org/10.15585/mmwr.mm7037e1
Article
CAS
PubMed
PubMed Central
Google Scholar
Tartof SY, Slezak JM, Fischer H et al (2021) Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet E-Pub. https://doi.org/10.1016/S0140-6736(21)02183-8
Article
Google Scholar
Havers FP, Pham H, Taylor CA, et al. COVID-19–associated hospitalizations among vaccinated and unvaccinated adults ≥18 years—COVID-NET, 13 states, January 1–July 24, 2021. medRxiv [Preprint posted online August 29, 2021]
Balakrishnan VS (2020) The arrival of Sputnik V. Lancet Infect Dis 20:1128. https://doi.org/10.1016/S1473-3099(20)30709-X
Article
CAS
PubMed
PubMed Central
Google Scholar
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf
Phillips EJ (2021) Allergic reactions after COVID-19 vaccination—putting risk into perspective. JAMA Netw Open 4:e2122326. https://doi.org/10.1001/jamanetworkopen.2021.22326
Article
PubMed
Google Scholar
Diaz GA, Parsons GT, Gering SK et al (2021) Myocarditis and pericarditis after vaccination for COVID-19. JAMA 326(12):1210–1212. https://doi.org/10.1001/jama.2021.13443
Article
CAS
PubMed
PubMed Central
Google Scholar
Franchini M, Liumbruno GM, Pezzo M (2021) COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 107:173–180. https://doi.org/10.1111/ejh.13665
Article
CAS
PubMed
Google Scholar
Dyer O (2021) Covid-19: regulators warn that rare Guillain-Barré cases may link to J&J and AstraZeneca vaccines. BMJ 374:1786. https://doi.org/10.1136/bmj.n1786
Article
Google Scholar
Cai C, Peng Y, Shen E et al (2021) A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther 29:2794–2805. https://doi.org/10.1016/j.ymthe.2021.08.001
Article
CAS
PubMed
PubMed Central
Google Scholar
Kadali RAK, Janagama R, Peruru S et al (2021) Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 93:4420–4429. https://doi.org/10.1002/jmv.26996
Article
CAS
PubMed
PubMed Central
Google Scholar
Sekiguchi K, Watanabe N, Miyazaki N et al (2021) Incidence of headache after COVID-19 vaccination in patients with history of headache: a cross-sectional study. Cephalalgia E-Pub. https://doi.org/10.1177/03331024211038654
Article
Google Scholar
Steiner TJ, Stovner LJ, Jensen R et al (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https://doi.org/10.1186/s10194-020-01208-0
Article
CAS
PubMed
PubMed Central
Google Scholar
Arroyo-Quiroz C, Kurth T, Cantu-Brito C et al (2014) Lifetime prevalence and underdiagnosis of migraine in a population sample of Mexican women. Cephalalgia 34(13):1088–1092. https://doi.org/10.1177/0333102414529196
Article
CAS
PubMed
Google Scholar
Fermo OP (2021) Underdiagnosis and undertreatment of migraine in Poland. Neurol Neurochir Pol 55(4):331–332. https://doi.org/10.5603/PJNNS.a2021.0046
Article
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 (W64)
Article
PubMed
Google Scholar
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5:210. https://doi.org/10.1186/s13643-016-0384-4
Article
PubMed
PubMed Central
Google Scholar
Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17:857–872. https://doi.org/10.1002/(sici)1097-0258(19980430)17:8%3c857::aid-sim777%3e3.0.co;2-e
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Article
CAS
PubMed
Google Scholar
Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Ann Math Stats 21:607–611
Article
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Article
PubMed
PubMed Central
Google Scholar
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. Cochrane, 2011. Available from https://handbook-5-1.cochrane.org/front_page.htm, last access 15/10/2021
Fu R, Gartlehner G, Grant M, et al. (2010) Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program. In: Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews. Rockville, MD. Available at: http://effectivehealthcare.ahrq.gov/ (last access 28/01/2022)
García-Grimshaw M, Ceballos-Liceaga SE, Hernández-Vanegas LE et al (2021) Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol 229:108786. https://doi.org/10.1016/j.clim.2021.108786
Article
CAS
PubMed
PubMed Central
Google Scholar
Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577
Article
CAS
PubMed
Google Scholar
Frenck RW Jr, Klein NP, Kitchin N et al (2021) Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 385(3):239–250. https://doi.org/10.1056/NEJMoa2107456
Article
CAS
PubMed
Google Scholar
d’Arminio Monforte A, Tavelli A, Perrone PM et al (2021) Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: data from 3,078 health care workers. EClinicalMedicine 36:100914. https://doi.org/10.1016/j.eclinm.2021.100914
Article
PubMed
PubMed Central
Google Scholar
Baldolli A, Michon J, Appia F et al (2021) Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: a case control study. Vaccine 39(32):4410–4413. https://doi.org/10.1016/j.vaccine.2021.06.054
Article
CAS
PubMed
PubMed Central
Google Scholar
Ossato A, Tessari R, Trabucchi C et al (2021) Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm 27:ejhpharm-2021-002933. https://doi.org/10.1136/ejhpharm-2021-002933 (E-Pub)
Article
Google Scholar
Nittner-Marszalska M, Rosiek-Biegus M, Kopeć A et al (2021) Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals. Vaccines (Basel) 9(6):553. https://doi.org/10.3390/vaccines9060553
Article
CAS
Google Scholar
Cuschieri S, Borg M, Agius S et al (2021) Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta’s state hospital. Int J Clin Pract 75(10):e14605. https://doi.org/10.1111/ijcp.14605
Article
CAS
PubMed
Google Scholar
Izumo T, Kuse N, Awano N et al (2021) Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan. Respir Investig 59(5):635–642. https://doi.org/10.1016/j.resinv.2021.06.003
Article
PubMed
PubMed Central
Google Scholar
Riad A, Pokorná A, Attia S et al (2021) Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 10(7):1428. https://doi.org/10.3390/jcm10071428
Article
CAS
PubMed
PubMed Central
Google Scholar
Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80(10):1330–1338. https://doi.org/10.1136/annrheumdis-2021-220647
Article
CAS
PubMed
Google Scholar
Kadali RAK, Janagama R, Peruru S et al (2021) Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis 106:376–381. https://doi.org/10.1016/j.ijid.2021.04.047
Article
CAS
PubMed
PubMed Central
Google Scholar
Borobia AM, Carcas AJ, Pérez-Olmeda M et al (2021) Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 398(10295):121–130. https://doi.org/10.1016/S0140-6736(21)01420-3
Article
CAS
PubMed
PubMed Central
Google Scholar
Bookstein Peretz S, Regev N, Novick L et al (2021) Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol 58(3):450–456. https://doi.org/10.1002/uog.23729
Article
CAS
PubMed
PubMed Central
Google Scholar
El-Shitany NA, Harakeh S, Badr-Eldin SM et al (2021) Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med 14:1389–1401. https://doi.org/10.2147/IJGM.S310497
Article
PubMed
PubMed Central
Google Scholar
Morales-Núñez JJ, Muñoz-Valle JF, Meza-López C et al (2021) Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines (Basel) 9(7):742. https://doi.org/10.3390/vaccines9070742
Article
CAS
Google Scholar
Lee YW, Lim SY, Lee JH et al (2021) Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci 36(21):e153. https://doi.org/10.3346/jkms.2021.36.e153
Article
CAS
PubMed
PubMed Central
Google Scholar
Lotan I, Wilf-Yarkoni A, Friedman Y et al (2021) Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel. Eur J Neurol 28(11):3742–3748. https://doi.org/10.1111/ene.15028
Article
PubMed
Google Scholar
Simon B, Rubey H, Treipl A et al (2021) Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant 36(9):1709–1716. https://doi.org/10.1093/ndt/gfab179
Article
CAS
PubMed
Google Scholar
Pimpinelli F, Marchesi F, Piaggio G et al (2021) Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol 14(1):81. https://doi.org/10.1186/s13045-021-01090-6
Article
CAS
PubMed
PubMed Central
Google Scholar
Cserep G, Morrow D, Latchford K et al (2021) The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study. Clin Exp Nephrol 26(1):54–58. https://doi.org/10.1007/s10157-021-02118-4 (E-Pub)
Article
CAS
PubMed
PubMed Central
Google Scholar
Abohelwa M, Elmassry M, Abdelmalek J et al (2021) 2019 Novel coronavirus vaccination among post-graduate residents and fellows. J Prim Care Community Health 12:21501327211022976. https://doi.org/10.1177/21501327211022978
Peled Y, Ram E, Lavee J et al (2021) BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant 40(8):759–762. https://doi.org/10.1016/j.healun.2021.04.003
Article
PubMed
PubMed Central
Google Scholar
Sahin U, Muik A, Derhovanessian E et al (2020) COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586(7830):594–599. https://doi.org/10.1038/s41586-020-2814-7
Article
CAS
PubMed
Google Scholar
Achiron A, Dolev M, Menascu S et al (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 27(6):864–870. https://doi.org/10.1177/13524585211003476
Article
CAS
PubMed
PubMed Central
Google Scholar
Tobaiqy M, Elkout H, MacLure K (2021) Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines (Basel) 9(4):393. https://doi.org/10.3390/vaccines9040393
Article
CAS
Google Scholar
Göbel CH, Heinze A, Karstedt S et al (2021) Headache attributed to vaccination against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther 10(2):1309–1330. https://doi.org/10.1007/s40122-021-00296-3
Article
PubMed
PubMed Central
Google Scholar
Jeon M, Kim J, Oh CE et al (2021) Adverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting system. J Korean Med Sci 36(17):e114. https://doi.org/10.3346/jkms.2021.36.e114
Article
CAS
PubMed
PubMed Central
Google Scholar
Pokharel K, Dawadi BR, Karki A (2021) Side effects after second dose of covishield vaccine among health care workers: a descriptive cross sectional study. JNMA J Nepal Med Assoc 59(238):577–579. https://doi.org/10.31729/jnma.6556
Article
PubMed
PubMed Central
Google Scholar
Logunov DY, Dolzhikova IV, Zubkova OV et al (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396(10255):887–897. https://doi.org/10.1016/S0140-6736(20)31866-3
Article
CAS
PubMed
PubMed Central
Google Scholar
Tanriover MD, Doğanay HL, Akova M et al (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398(10296):213–222. https://doi.org/10.1016/S0140-6736(21)01429-X
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang G, Zhu L, Zhu Y et al (2021) Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China. Hum Vaccin Immunother 17(9):2863–2867. https://doi.org/10.1080/21645515.2021.1913964
Article
CAS
PubMed
PubMed Central
Google Scholar
Avcı H, Karabulut B, Eken HD et al (2021) Otolaryngology-specific symptoms may be highly observed in patients with a history of Covid-19 infection after inactivated coronavirus vaccination. Ear Nose Throat J 8:1455613211028493. https://doi.org/10.1177/01455613211028493 (E-Pub)
Article
Google Scholar
Zhang MX, Zhang TT, Shi GF et al (2021) Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines 20(7):891–898. https://doi.org/10.1080/14760584.2021.1925112
Article
CAS
PubMed
Google Scholar
Djanas D, Yusirwan MRD et al (2021) Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data Brief 36:107098. https://doi.org/10.1016/j.dib.2021.107098
Article
PubMed
PubMed Central
Google Scholar
Riad A, Sağıroğlu D, Üstün B et al (2021) Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med 10(12):2629. https://doi.org/10.3390/jcm10122629
Article
CAS
PubMed
PubMed Central
Google Scholar
Han B, Song Y, Li C et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis 21(12):1645–1653. https://doi.org/10.1016/S1473-3099(21)00319-4
Article
CAS
PubMed
PubMed Central
Google Scholar
Jackson LA, Anderson EJ, Rouphael NG et al (2020) An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 383(20):1920–1931. https://doi.org/10.1056/NEJMoa2022483
Article
CAS
PubMed
Google Scholar
Anderson EJ, Rouphael NG, Widge AT et al (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383(25):2427–2438. https://doi.org/10.1056/NEJMoa2028436
Article
CAS
PubMed
Google Scholar
Heath PT, Galiza EP, Baxter DN et al (2021) Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 385(13):1172–1183. https://doi.org/10.1056/NEJMoa2107659
Article
CAS
PubMed
Google Scholar
Shinde V, Bhikha S, Hoosain Z et al (2021) Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 384(20):1899–1909. https://doi.org/10.1056/NEJMoa2103055
Article
CAS
PubMed
PubMed Central
Google Scholar
Keech C, Albert G, Cho I et al (2020) Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 383(24):2320–2332. https://doi.org/10.1056/NEJMoa2026920
Article
CAS
PubMed
Google Scholar
Xia S, Zhang Y, Wang Y et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 21(1):39–51. https://doi.org/10.1016/S1473-3099(20)30831-8
Article
CAS
PubMed
Google Scholar
Guo W, Duan K, Zhang Y et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine 38:101010. https://doi.org/10.1016/j.eclinm.2021.101010
Article
PubMed
PubMed Central
Google Scholar
Xia S, Duan K, Zhang Y et al (2020) Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324(10):951–960. https://doi.org/10.1001/jama.2020.15543
Article
CAS
PubMed
Google Scholar
Zhu FC, Guan XH, Li YH et al (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396(10249):479–488. https://doi.org/10.1016/S0140-6736(20)31605-6
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu FC, Li YH, Guan XH et al (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395(10240):1845–1854. https://doi.org/10.1016/S0140-6736(20)31208-3
Article
CAS
PubMed
PubMed Central
Google Scholar
Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–2201. https://doi.org/10.1056/NEJMoa2101544
Article
CAS
PubMed
Google Scholar
Pagotto V, Ferloni A, Mercedes Soriano M et al (2021) Active monitoring of early safety of Sputnik V vaccine in Buenos Aires. Argentina Medicina (B Aires) 81(3):408–414
CAS
Google Scholar
Menni C, Klaser K, May A et al (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 21(7):939–949. https://doi.org/10.1016/S1473-3099(21)00224-3
Article
CAS
PubMed
PubMed Central
Google Scholar
Al Kaabi N, Zhang Y, Xia S et al (2021) Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 326(1):35–45. https://doi.org/10.1001/jama.2021.8565
Article
CAS
PubMed
Google Scholar
Shimabukuro TT, Kim SY, Myers TR et al (2021) Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med 384(24):2273–2282. https://doi.org/10.1056/NEJMoa2104983
Article
CAS
PubMed
Google Scholar
Bae S, Lee YW, Lim SY et al (2021) Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci 36(17):e115. https://doi.org/10.3346/jkms.2021.36.e115
Article
CAS
PubMed
PubMed Central
Google Scholar
Park MJ, Choi YJ, Choi S (2021) Emergency department utilization by in-hospital healthcare workers after COVID-19 vaccination. J Korean Med Sci 36(27):e196. https://doi.org/10.3346/jkms.2021.36.e196
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim T, Park SY, Yu S et al (2021) Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 Anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Republic of Korea. Vaccines (Basel) 9(6):648. https://doi.org/10.3390/vaccines9060648
Article
CAS
Google Scholar
McLaurin-Jiang S, Garner CD, Krutsch K et al (2021) Maternal and child symptoms following COVID-19 vaccination among breastfeeding mothers. Breastfeed Med 16(9):702–709. https://doi.org/10.1089/bfm.2021.0079
Article
PubMed
Google Scholar
Song JY, Cheong HJ, Kim SR et al (2021) Early safety monitoring of COVID-19 vaccines in healthcare workers. J Korean Med Sci 36(15):e110. https://doi.org/10.3346/jkms.2021.36.e110
Article
CAS
PubMed
PubMed Central
Google Scholar
Hatmal MM, Al-Hatamleh MAI, Olaimat AN et al (2021) Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines (Basel) 9(6):556. https://doi.org/10.3390/vaccines9060556
Article
CAS
Google Scholar
Kim SH, Wi YM, Yun SY et al (2021) Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci 36(14):e107. https://doi.org/10.3346/jkms.2021.36.e107
Article
CAS
PubMed
PubMed Central
Google Scholar
Powell AA, Power L, Westrop S et al (2021) Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021. England Euro Surveill 26(28):2100634. https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100634
Article
CAS
Google Scholar
Al Khames Aga QA, Alkhaffaf WH, Hatem TH et al (2021) Safety of COVID-19 vaccines. J Med Virol 93(12):6588–6594. https://doi.org/10.1002/jmv.27214
Article
CAS
PubMed
Google Scholar
Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P et al (2021) The incidence and severity of post-vaccination reactions after vaccination against COVID-19. Vaccines (Basel) 9(5):502. https://doi.org/10.3390/vaccines9050502
Article
CAS
Google Scholar
Shu YJ, He JF, Pei RJ et al (2021) Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chin Med J (Engl) 134(16):1967–1976. https://doi.org/10.1097/CM9.0000000000001702
Article
Google Scholar
Meng FY, Gao F, Jia SY et al (2021) Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther 6(1):271. https://doi.org/10.1038/s41392-021-00692-3
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang S, Li Y, Dai L et al (2021) Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 21(8):1107–1119. https://doi.org/10.1016/S1473-3099(21)00127-4
Article
PubMed
PubMed Central
Google Scholar
Cherian S, Paul A, Ahmed S et al (2021) Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int 41(8):1441–1445. https://doi.org/10.1007/s00296-021-04917-0
Article
CAS
PubMed
PubMed Central
Google Scholar
Andrzejczak-Grządko S, Czudy Z, Donderska M (2021) Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci 25(12):4418–4421. https://doi.org/10.26355/eurrev_202106_26153
Article
PubMed
Google Scholar
Ou MT, Boyarsky BJ, Chiang TPY et al (2021) Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation 105(9):2119–2123. https://doi.org/10.1097/TP.0000000000003824
Article
CAS
PubMed
Google Scholar
Quiroga B, Sánchez-Álvarez E, Goicoechea M et al (2021) COVID-19 vaccination among Spanish nephrologists: acceptance and side effects. J Healthc Qual Res 36(6):363–369. https://doi.org/10.1016/j.jhqr.2021.05.002
Article
CAS
PubMed
PubMed Central
Google Scholar
Pan HX, Liu JK, Huang BY et al (2021) Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl) 134(11):1289–1298. https://doi.org/10.1097/CM9.0000000000001573
Article
Google Scholar
Alhazmi A, Alamer E, Daws D et al (2021) Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines (Basel) 9(6):674. https://doi.org/10.3390/vaccines9060674
Article
CAS
Google Scholar
Abu-Hammad O, Alduraidi H, Abu-Hammad S et al (2021) Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. Vaccines (Basel) 9(6):577. https://doi.org/10.3390/vaccines9060577
Article
CAS
Google Scholar
Wang J, Hou Z, Liu J et al (2021) Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol 75(2):439–441. https://doi.org/10.1016/j.jhep.2021.04.026
Article
CAS
PubMed
PubMed Central
Google Scholar
Campello E, Simion C, Bulato C et al (2021) Absence of hypercoagulability after nCoV-19 vaccination: an observational pilot study. Thromb Res 205:24–28. https://doi.org/10.1016/j.thromres.2021.06.016
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang J, Hu Z, He J et al (2021) Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled. Phase I trial Emerg Microbes Infect 10(1):1589–1597. https://doi.org/10.1080/22221751.2021.1951126
Article
CAS
PubMed
Google Scholar
Ward BJ, Gobeil P, Séguin A et al (2021) Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med 27(6):1071–1078. https://doi.org/10.1038/s41591-021-01370-1
Article
CAS
PubMed
PubMed Central
Google Scholar
Zdziarski K, Landowski M, Zabielska P et al (2021) Subjective feelings of polish doctors after receiving the COVID-19 vaccine. Int J Environ Res Public Health 18(12):6291. https://doi.org/10.3390/ijerph18126291
Article
CAS
PubMed
PubMed Central
Google Scholar
Goepfert PA, Fu B, Chabanon AL et al (2021) Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis 21(9):1257–1270. https://doi.org/10.1016/S1473-3099(21)00147-X
Article
CAS
PubMed
PubMed Central
Google Scholar
Hwang YH, Song KH, Choi Y et al (2021) Can reactogenicity predict immunogenicity after COVID-19 vaccination? Korean J Intern Med 36(6):1486–1491. https://doi.org/10.3904/kjim.2021.210
Article
PubMed
PubMed Central
Google Scholar
Chappell KJ, Mordant FL, Li Z et al (2021) Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 21(10):1383–1394. https://doi.org/10.1016/S1473-3099(21)00200-0
Article
CAS
PubMed
PubMed Central
Google Scholar
von Wrede R, Pukropski J, Moskau-Hartmann S et al (2021) COVID-19 vaccination in patients with epilepsy: first experiences in a German tertiary epilepsy center. Epilepsy Behav 122:108160. https://doi.org/10.1016/j.yebeh.2021.108160
Article
Google Scholar
Mulligan MJ, Lyke KE, Kitchin N et al (2020) Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586(7830):589–593. https://doi.org/10.1038/s41586-020-2639-4
Article
CAS
PubMed
Google Scholar
Tebas P, Yang S, Boyer JD et al (2021) Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 31:100689. https://doi.org/10.1016/j.eclinm.2020.100689
Article
PubMed
Google Scholar
Ruddy JA, Boyarsky BJ, Bailey JR et al (2021) Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. AIDS 35(14):2399–2401. https://doi.org/10.1097/QAD.0000000000003017
Article
CAS
PubMed
Google Scholar
García-Azorín D, Do TP, Gantenbein AR et al (2021) Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain 22(1):108. https://doi.org/10.1186/s10194-021-01324-5
Article
CAS
PubMed
PubMed Central
Google Scholar
Perrotta A, Biondi-Zoccai G, Saade W et al (2021) A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med 63(3):324–331. https://doi.org/10.23736/S0031-0808.21.04435-9
Article
PubMed
Google Scholar
Ekizoglu E, Gezegen H, Yalınay Dikmen P et al (2021) The characteristics of COVID-19 vaccine-related headache: clues gathered from the healthcare personnel in the pandemic. Cephalalgia E-Pub. https://doi.org/10.1177/03331024211042390
Article
Google Scholar
Hatmi ZN (2021) A systematic review of systematic reviews on the COVID-19 pandemic. SN Compr Clin Med 3:419–436. https://doi.org/10.1007/s42399-021-00749-y
Article
CAS
PubMed
PubMed Central
Google Scholar
Leonardi M, Lee H, van der Veen S et al (2020) Avoiding the banality of evil in times of COVID-19: thinking differently with a biopsychosocial perspective for future health and social policies development. SN Compr Clin Med 2:1758–1760. https://doi.org/10.1007/s42399-020-00486-8
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu S, He M, Liu R et al (2013) Headache yesterday in China: a new approach to estimating the burden of headache, applied in a general-population survey in China. Cephalalgia 33(15):1211–1217. https://doi.org/10.1177/0333102413490347
Article
PubMed
Google Scholar
Andrée C, Steiner TJ, Barré J et al (2014) Headache yesterday in Europe. J Headache Pain 15:33. https://doi.org/10.1186/1129-2377-15-33
Article
PubMed
PubMed Central
Google Scholar
Ayzenberg I, Katsarava Z, Sborowski A et al (2015) Headache yesterday in Russia: its prevalence and impact, and their application in estimating the national burden attributable to headache disorders. J Headache Pain 15:7. https://doi.org/10.1186/1129-2377-16-7
Article
PubMed
Google Scholar
Steiner TJ, Rao GN, Kulkarni GB et al (2016) Headache yesterday in Karnataka state, India: prevalence, impact and cost. J Headache Pain 17:74. https://doi.org/10.1186/s10194-016-0669-y
Article
PubMed
PubMed Central
Google Scholar
Salih F, Schönborn L, Kohler S et al (2021) Vaccine-induced thrombocytopenia with severe headache. N Engl J Med 385(22):2103–2105. https://doi.org/10.1056/NEJMc2112974
Article
PubMed
Google Scholar
Göbel CH, Heinze A, Karstedt S et al (2021) Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 3(3):fcab169. https://doi.org/10.1093/braincomms/fcab169
Article
CAS
PubMed
PubMed Central
Google Scholar
Baig AM, Khaleeq A, Ali U et al (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11:995–998. https://doi.org/10.1021/acschemneuro.0c00122
Article
CAS
PubMed
Google Scholar
Bougakov D, Podell K, Goldberg E (2021) Multiple Neuroinvasive Pathways in COVID-19. Mol Neurobiol 58(2):564–575. https://doi.org/10.1007/s12035-020-02152-5
Article
CAS
PubMed
Google Scholar
MaassenVanDenBrink A, de Vries T, Danser AHJ (2020) Headache medication and the COVID-19 pandemic. J Headache Pain 21:38. https://doi.org/10.1186/s10194-020-01106-5
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu Y, Xu X, Yang L et al (2020) Nervous system damage after COVID-19 infection: presence or absence? Brain Behav Immun 87:55. https://doi.org/10.1016/j.bbi.2020.04.043
Article
CAS
PubMed
PubMed Central
Google Scholar
Harapan BN, Yoo HJ (2021) Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol 268:3059–3071. https://doi.org/10.1007/s00415-021-10406-y
Article
CAS
PubMed
PubMed Central
Google Scholar
Caronna E, Pozo-Rosich P (2021) Headache as a symptom of COVID-19: narrative review of 1-year research. Curr Pain Headache Rep 25:73. https://doi.org/10.1007/s11916-021-00987-8
Article
PubMed
PubMed Central
Google Scholar
Chou SH, Beghi E, Helbok R et al (2021) GCS-NeuroCOVID consortium and energy consortium. Global incidence of neurological manifestations among patients hospitalized with COVID-19 – a report for the GCS-NeuroCOVID consortium and the energy consortium. JAMA Netw Open 4:e2112131. https://doi.org/10.1001/jamanetworkopen.2021.12131
Article
PubMed
PubMed Central
Google Scholar
Borges do Nascimento IJ, Cacic N, Abdulazeem HM et al (2020) Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 9:941. https://doi.org/10.3390/jcm9040941
Lechien JR, Chiesa-Estomba CM, Place S et al (2020) Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 288:335–344. https://doi.org/10.1111/joim.13089
Article
CAS
PubMed
Google Scholar
Liguori C, Pierantozzi M, Spanetta M et al (2020) Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain Behav Immun 88:11–16. https://doi.org/10.1016/j.bbi.2020.05.037
Article
CAS
PubMed
PubMed Central
Google Scholar
O’Keefe JB, Tong EJ, O’Keefe GD et al (2021) Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study. BMJ Open 11:e044154. https://doi.org/10.1136/bmjopen-2020-044154
Article
PubMed
Google Scholar
Straburzyński M, Nowaczewska M, Budrewicz S et al (2021) COVID-19-related headache and sinonasal inflammation: a longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection. Cephalalgia 20:3331024211040753. https://doi.org/10.1177/03331024211040753 (E-Pub)
Article
Google Scholar
Bolay H, Gül A, Baykan B (2020) COVID-19 is a real headache! Headache 60:1415–1421. https://doi.org/10.1111/head.13856
Article
PubMed
Google Scholar
Bobker SM, Robbins MS (2021) Virtual issue: COVID-19 and headache. Headache 61:412–413. https://doi.org/10.1111/head.14085
Article
PubMed
PubMed Central
Google Scholar
Messlinger K, Neuhuber W, May A (2021) Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19. Cephalalgia 42(2):176–180. https://doi.org/10.1177/03331024211036665 (E-Pub)
Article
PubMed
PubMed Central
Google Scholar
Collignon C, Bol V, Chalon A et al (2020) Innate immune responses to chimpanzee adenovirus vector 155 vaccination in mice and monkeys. Front Immunol 11:579872. https://doi.org/10.3389/fimmu.2020.579872
Article
CAS
PubMed
PubMed Central
Google Scholar
Bergamaschi C, Terpos E, Rosati M et al (2021) Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep 36:109504. https://doi.org/10.1016/j.celrep.2021.109504
Article
CAS
PubMed
PubMed Central
Google Scholar
Pépin S, Donazzolo Y, Jambrecina A et al (2013) Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31:5572–5578. https://doi.org/10.1016/j.vaccine.2013.08.069
Article
CAS
PubMed
Google Scholar
Trigo López J, García-Azorín D, Planchuelo-Gómez Á et al (2020) Phenotypic characterization of acute headache attributed to SARS-CoV-2: an ICHD-3 validation study on 106 hospitalized patients. Cephalalgia 40:1432–1442. https://doi.org/10.1177/0333102420965146
Article
Google Scholar
Wang YH, Huang LY, Chen YL et al (2021) ChAdOx1 COVID-19 vaccine-induced thrombocytopenia syndrome. QJM 114:733–734. https://doi.org/10.1093/qjmed/hcab221
Article
CAS
PubMed
Google Scholar
Giovane R, Campbell J (2021) Bilateral thalamic stroke: a case of COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) or a coincidence due to underlying risk factors? Cureus 13(10):e18977. https://doi.org/10.7759/cureus.18977
Article
PubMed
PubMed Central
Google Scholar